



Inspired by **patients.**
Driven by **science.**

Cancelled before Active Statement

Statement of Discontinuation of the study
Name of Sponsor: UCB BIOSCIENCES GmbH
Study No: 2011-002517-11
Product: Olokizumab
Title: A multi-centre, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, tolerability, and pharmacokinetic of olokizumab administered subcutaneously to subjects with moderate to severe Crohn's disease
Phase: 2
Study Period: NA
Centres: NA
Number of Subjects: 0
Publications: NA
Statement on discontinuation of the study: Discontinued during preparation of the trial. No participants entered the study, therefore no results / data are available.